You are here

Merck

Big pharma freshens up

EP Vantage

Fri, 04/9/21 - 10:35 am

Bristol Myers Squibb

Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use

Fierce Pharma

Thu, 04/8/21 - 11:13 am

renal cell carcinoma

clinical trials

Former Merck Exec Joins Flagship to Helm AI Startup Generate Biomedicines

BioSpace

Wed, 03/31/21 - 11:02 pm

Generate Biomedicines

Merck sets up $240M Alydia Health buyout to beef up its future Organon women's health spinout

Fierce Biotech

Tue, 03/30/21 - 10:13 pm

Go or no go? The FDA plays hardball

EP Vantage

Tue, 03/30/21 - 11:47 am

Bristol Myers Squibb

accelerated approvals

FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm

Endpoints

Mon, 03/29/21 - 11:09 pm

triple negative breast cancer

FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm

Endpoints

Mon, 03/29/21 - 11:09 pm

triple negative breast cancer

How Gilead's and Merck's Surprise Partnership Will Shake Up the HIV Market

Motley Fool

Thu, 03/25/21 - 11:46 am

Gilead Sciences

drug development

Merck Scores Latest Label Expansion for Keytruda in Esophageal Carcinomas

BioSpace

Tue, 03/23/21 - 11:23 pm

esophageal cancer

Merck breathes a sigh of relief as Keytruda-Lenvima combo aces confirmatory study in endometrial cancer

Endpoints

Fri, 03/19/21 - 10:51 am

clinical trials

endometrial cancer

Merck's marketing chief leaves; commercial chief takes over

Beckers Hospital Review

Thu, 03/18/21 - 08:40 pm

Merck Enters Into New Collab to Advance Neurodegenerative Candidates With Amathus

BioSpace

Wed, 03/17/21 - 11:24 pm

Amathus Therapeutics

neurodegenerative disease

4 Pharma Stocks That Could Be Losers With the $1.9 Trillion Stimulus Package

Motley Fool

Wed, 03/17/21 - 10:39 am

Jazz Pharmaceuticals

Merck wins priority review for rare carcinoma drug belzutifan, the centerpiece of $1B+ Peloton buyout

Endpoints

Tue, 03/16/21 - 10:54 am

Peloton Therapeutics

renal cell carcinoma

priority review

Gilead, Merck combine forces in HIV

BioPharma Dive

Mon, 03/15/21 - 11:51 pm

Gilead Sciences

Industry-wide accelerated approval review yields four withdrawals

RAPS.org

Wed, 03/10/21 - 10:53 pm

Bristol-Meyers Squibb

accelerated approvals

Surface Oncology To Test SRF388 Plus Keytruda Combo In Solid Tumor Settings

Benzinga

Tue, 03/9/21 - 09:39 pm

Surface Oncology

Clarivate Drugs to Watch Report Highlights Four Likely Blockbusters Among Drugs Launching in 2021

PR Newswire

Tue, 03/9/21 - 10:45 am

Merck reports positive early data for its experimental COVID-19 pill

Beckers Hospital Review

Mon, 03/8/21 - 09:30 pm

Ridgeback Biotherapeutics

clinical trials

Merck discard jumps straight to the top of the chart of the most expensive drugs in the US at $1M-plus

Endpoints

Mon, 03/8/21 - 09:24 pm

Eiger Pharmaceuticals

Pages